US2020197310A1PendingUtilityA1

Technology for Preparation of Macromolecular Microspheres

68
Assignee: ANSUN BIOPHARMA INCPriority: Jan 24, 2006Filed: Mar 9, 2020Published: Jun 25, 2020
Est. expiryJan 24, 2026(expired)· nominal 20-yr term from priority
Y02A50/30A61K 9/0073A61K 9/1617A61K 38/47A61K 9/19A61P 33/06A61K 9/1682A61K 9/14C12Y 302/01018A61P 3/10A61K 9/1623A61K 9/1647A61K 38/57A61P 31/04A61P 31/16A61K 38/18A61P 35/00Y10T428/2982A61K 38/16A61P 29/00A61P 25/16A61P 23/00A61P 3/02Y02A50/483Y02A50/469Y02A50/47Y02A50/402Y02A50/385Y02A50/401Y02A50/491Y02A50/411Y02A50/478Y02A50/48Y02A50/471Y02A50/387Y02A50/393A61K 9/1694
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . Microparticles comprising a polypeptide comprising the amino acid of SEQ ID NO:17 prepared by a method comprising:
 a) adding a counterion selected from the group consisting of sodium citrate, sodium sulfate, calcium sulfate, potassium sulfate and magnesium sulfate to an aqueous solution comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:17, whereby an aqueous composition is formed;   b) adding isopropanol to the aqueous composition of (a) whereby a second aqueous composition is formed; and   c) cooling the second aqueous composition of (b) at a rate of 0.1° C./min to 10° C./min to a temperature between 4° C. and −45° C., whereby a composition containing polypeptide microparticles comprising the polypeptide is formed.   
     
     
         2 . The microparticles of  claim 1 , wherein the cooling rate is 0.5° C./min to 2° C./min. 
     
     
         3 . The microparticles of  claim 1 , wherein the cooling rate is 0.5° C./min to 1° C./min. 
     
     
         4 . The microparticles of  claim 1 , wherein the counterion is sodium citrate. 
     
     
         5 . The microparticles of  claim 1 , wherein the counterion is magnesium sulfate. 
     
     
         6 . The microparticles of  claim 1 , wherein the method of making further comprises cooling the composition containing polypeptide microparticles comprising the polypeptide to a temperature of between about −45° C. and about −80° C. 
     
     
         7 . The microparticles of  claim 1 , wherein step c) comprises cooling the second aqueous composition of (b) to a temperature between 2° C. and −20° C. degrees. 
     
     
         8 . The microparticles of  claim 1 , wherein step b) comprises adding isopropanol to about 10% v/v. 
     
     
         9 . The microparticles of  claim 1 , wherein step b) comprises adding isopropanol to about 20% v/v. 
     
     
         10 . The microparticles of  claim 1 , wherein wherein step b) comprises adding isopropanol to about 30% v/v. 
     
     
         11 . The microparticles of  claim 1 , wherein the method of making further comprises lyophilizing the composition containing polypeptide microparticles to obtain a dry powder. 
     
     
         12 . The microparticles of  claim 1 , wherein the diameter of the microparticles is between 0.5 μm and 10 μm. 
     
     
         13 . The composition of  claim 12 , wherein the diameter of the microparticles is between 0.5 μm or and 5.0 μm. 
     
     
         14 . A composition comprising microparticles of a polypeptide comprising the amino acid sequence of SEQ ID NO:17 and magnesium sulfate or sodium sulfate, wherein the microparticles have a diameter 
     
     
         15 . The microparticles of  claim 14 , wherein the diameter of the microparticles is between 0.5 μm and 10 μm. 
     
     
         16 . The composition of  claim 15 , wherein the diameter of the microparticles is between 0.5 μm or and 5.0 μm.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.